Bristol-Myers Squibb (BMY) Stock Rises 1.78% (November 13, 2026): Up 2.1% in Five Sessions
Technical analysis of BMY stock on November 13, 2026: price 63.43 USD, trend uptrend, RSI 55.9, support 58.83, resistance 64.19.

Why BMY is in focus today
Selected automatically from 8 NYSE (US) stocks by a technical-signal score with daily weighted randomisation — not a recommendation.
Trend & Price Action
The share price closed above both the 20-day simple moving average (SMA20), at $62.08, and the 50-day average, at $61.90. The SMA20 rose 1.62% over five days, and its same-session move above the SMA50 formed a golden cross, a signal that shorter-term price direction has strengthened relative to the medium-term trend. The combination supports the uptrend, though a moving-average cross is a lagging measure and does not by itself guarantee further gains. BMY stands at 86% of its 20-session range, between support at $58.83 and resistance at $64.19. It is also approaching the upper Bollinger band at $64.35; the band’s 7.3% width is narrowing, a squeeze that can precede a larger move but does not indicate its direction.
Oscillators & Momentum
Momentum readings are positive but not stretched. The RSI is 55.9, in neutral territory, while Stochastic %K at 61.9 and %D at 52.1 are also neutral. Those readings suggest the recent advance has not yet pushed the shares into technically overbought territory. The MACD is above its signal line, with a positive histogram, pointing to positive momentum consistent with the uptrend. The indicators therefore broadly confirm the price structure, while leaving room for the share price to meet resistance near the upper band.
Volatility & Volume
The average true range (ATR), a measure of typical price movement, is $1.72, or 2.7% of the share price, indicating moderate volatility. That makes a breakout from the narrowing Bollinger bands plausible, but it also means ordinary daily swings could test nearby levels. Friday’s volume was 9,273,900 shares, about 0.9 times the 20-day average of 10,115,415. Participation was therefore lighter than usual despite the price gain. On-balance volume (OBV), which tracks whether volume tends to accompany rising or falling prices, is rising and offers a supportive signal, though the below-average session volume tempers the confirmation.Key Levels & Scenarios
A sustained move through resistance at $64.19 and the upper Bollinger band at $64.35 would strengthen the case that the squeeze is resolving upward. Failure to clear that area could leave BMY consolidating above its moving averages; a drop below the SMA20 at $62.08 would weaken the near-term setup, while the 20-session support at $58.83 marks a deeper reference point. The three-month high is $68.64 and the low is $56.15.Fundamental Context
According to its SEC filing, Bristol-Myers Squibb reported revenue of $13.07 billion for the quarter ended September 30, 2026, up 6.9% from $12.22 billion a year earlier. Net income was $2.16 billion, compared with $2.20 billion in the year-earlier quarter, and diluted earnings per share were $1.05. The revenue increase alongside slightly lower net income shows that sales growth did not translate into higher profit for the period.Technical Verdict: BUY
The JournalArta Research verdict is BUY, based on a +92 score, with three bullish technical signals and no bearish signals. The case rests on the same-session golden cross, the price holding above its 50-day average, and rising OBV confirming the uptrend. The RSI at 55.9 remains neutral, while below-average volume is a caution on the strength of participation. The verdict is invalidated if the price falls below the specified stop loss of $60.50. - Entry range: $62.15–$63.43 - Exit targets: $67.82 (target 1) and $72.22 (target 2) - Stop-loss protection: $60.50 - Valid until: December 12, 2026 In plain English, the technical signals currently favor further gains, but a fall below $60.50 would break the setup.Summary Data BMY
| Last price | 63.43 USD |
| Change 1 day / 5 days / 1 month | 1.78% / 2.08% / 6.16% |
| Trend / MA-cross | uptrend / golden |
| SMA20 / SMA50 | 62.08 / 61.90 |
| RSI (14) / Stochastic %K | 55.9 / 61.9 |
| Bollinger %B / ATR | 80% / 1.72 |
| Support / Resistance 20 days | 58.83 / 64.19 |
| Data as of | 14 November 2026 04:00 WIB |
| JournalArta research verdict (score) | Buy (+92) |
| Entry zone | 62.15 – 63.43 |
| Target 1 / 2 | 67.82 / 72.22 |
| Stop loss | 60.50 |
| Reward/risk | 1.5 / 3.0 |
Today's full Buy and Sell list for US stocks →
Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.
Track BMY stock price daily: live levels, support/resistance and our full BMY analysis history.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1I’m A Celebrity 2026 Line-Up: Rooney Leads 11 Stars Into Jungle

- 2Mavericks Surfers Race to California for Waves Near 50 Feet

- 3NYC Medical Examiner Has Not Determined Cause of Death of Beau Rose Jessup

- 4Mountaineer Finds Ice Age Cave Bear Graveyard in the Dolomites

- 5Rugby League World Cup Final 2026: Kick-Off Times and How to Watch Kangaroos v New Zealand

Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits











